Compass Therapeutics, Inc.
CMPX
$5.28
$0.061.15%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -35.69% | -5.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.92% | 17.25% | |||
| Operating Income | 24.92% | -17.25% | |||
| Income Before Tax | 28.28% | -19.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.28% | -19.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.28% | -19.53% | |||
| EBIT | 24.92% | -17.25% | |||
| EBITDA | 24.65% | -17.61% | |||
| EPS Basic | 41.24% | -19.53% | |||
| Normalized Basic EPS | 41.27% | -19.55% | |||
| EPS Diluted | 41.24% | -19.53% | |||
| Normalized Diluted EPS | 41.27% | -19.55% | |||
| Average Basic Shares Outstanding | 22.06% | 0.03% | |||
| Average Diluted Shares Outstanding | 22.06% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||